# US 2012/0083462 A1 · Pharmaceutical anti-infective composition for inhalation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0083462 A1
- Document ID: US20120083462A1
- Status: Published application
- Kind: A1
- Application number: 13/137,826
- Filed: 2011-09-15
- Published: 2012-04-05
- Earliest claimed: 2007-10-11
- Inventors: Arthur Deboeck; Philippe Baudier; Francis Vanderbist
- Web page: https://patentgrep.com/patent/US20120083462A1

## CPC

- A61K 31/7052: having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- A61K 9/4816: {Wall or shell material}
- A61K 31/7032: attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
- A61K 31/7036: having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/28: Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
- A61P 31/04: Antibacterial agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An anti-infective composition for inhalation, containing, at least an effective amount of an antimicrobial aminoglycoside compound or a salt thereof; and an effective amount of a biofilm modifier which is a macrolide compound or salt thereof.

## Claims

### Claim at position 1

1-23. (canceled)

### Claim 24

A composition for inhalation, comprising at least:
(a) an effective amount of an antimicrobial aminoglycoside compound or a salt thereof, and
(b) an effective amount of a biofilm modifier which is a macrolide derivative or salt thereof.

### Claim 25 (depends on 24)

The composition of claim 24, in a form of a dry powder.

### Claim 26 (depends on 24)

The composition according to claim 24, in a form of a suspension, solution, or a combination thereof.

### Claim 27 (depends on 24)

The composition of claim 24, wherein a ratio (weight/weight) of each of said aminoglycoside compound and said macrolide is greater or equal to 10% of said composition.

### Claim 28 (depends on 27)

The composition of claim 27, wherein the ratio is between 10-99% of the composition.

### Claim 29 (depends on 28)

The composition of claim 28, wherein the ratio is between 15-90% of the composition.

### Claim 30 (depends on 24)

The composition of claim 24, wherein a ratio (weight/weight) aminoglycoside/macrolide is between 0.2 to 5.

### Claim 31 (depends on 30)

The composition of claim 30, wherein the ratio is between 0.3 and 3.

### Claim 32 (depends on 31)

The composition of claim 31, wherein the ratio is between 0.8 and 2.

### Claim 33 (depends on 24)

The composition of claim 24, wherein a sum of active ingredients represents more than 20% (weight/weight) of the composition.

### Claim 34 (depends on 33)

The composition claim 33, wherein the sum of the active, ingredients is more than 30% of the composition.

### Claim 35 (depends on 34)

The composition of claim 34, wherein the sum of the active ingredients in more than 40% of the composition.

### Claim 36 (depends on 24)

The composition of claim 24, containing at least one or more pharmaceutically acceptable excipients.

### Claim 37 (depends on 36)

The composition of claim 36, wherein at least one of said pharmaceutically acceptable excipients is a carbohydrate or a mixture of two or more carbohydrates.

### Claim 38 (depends on 37)

The composition of claim 37, wherein at least one of said pharmaceutically acceptable carbohydrate comprises anhydrous lactose, lactose monohydrate, mannitol, xylitol, dextrose, saccharose, a cyclodextrin compound or a mixture thereof.

### Claim 39 (depends on 36)

The composition of claim 36, wherein at least one of said pharmaceutically acceptable excipient is a lipidic excipient.

### Claim 40 (depends on 39)

The composition of claim 39, wherein at least one of said lipidic excipients comprises cholesterol and derivatives, phospholipid, ethers of fatty alcohols, esters of fatty acids, hydrogenated oils, polyoxyethylenated derivatives, esters of glycerol.

### Claim 41 (depends on 40)

The composition of claim 40, wherein said composition contains a mixture of cholesterol or a cholesterol compound and a phospholipid or a phospholipid.

### Claim 42 (depends on 24)

The composition of claim 24, further containing one or more chelating agent(s).

### Claim 43 (depends on 42)

The composition of claim 42, wherein the chelating agent is edetic acid, citric acid, malic acid or a salt thereof.

### Claim 44 (depends on 24)

The composition of claim 24, further containing one or more antioxidant(s).

### Claim 45 (depends on 44)

The composition of claim 44, wherein at least one antioxidant comprises a cystein compound, of ascorbic acid compounds, tocopherol compounds, propylgallate, butylhydroxyanisole, or butylhydroxytoluene.

### Claim 46 (depends on 24)

The composition of claim 24, wherein the aminoglyscoside compound is Tobramycin, Kanamycin, Streptomycin, Gentamicin, Amikacin, Apramycin, Arbekacin, Bekanamycin, Astromycin, Dihydrostreptomycin, Framycetin, Neomycin, Netilmicin, Isepamicin, Micronomicin, Sisomicin or a pharmaceutically acceptable salt thereof.

### Claim 47 (depends on 24)

The composition of claim 24, wherein the macrolide compound is a biofilm modifier macrolide or an antibiotic macrolide, and comprises of Clarithromycin, Azithromycin, Roxithromycin, Erythromycin, Telithromycin, Dirithromycin, Flurithromycin, Josamycin, Kitasamycin, Midecamycin, Dalfopristin, Oleandomycin, Midecamycin, Pristinamycin, Rokitamycin, Spiramycin, Tilmicosin, Troleandomycin, Tylosin, Virginiamycin, and the pharmaceutically acceptable salts.

### Claim 48 (depends on 24)

The composition of claim 24, wherein the aminoglyscoside compound is Tobramycin or a salt thereof and the macrolide compound is clarithromycin or a salt thereof, said composition being free of another antimicrobial agent.

### Claim 49 (depends on 24)

The composition of claim 24, wherein said composition is free of excipients.

### Claim 50 (depends on 25)

The composition of claim 25, wherein said dry powder composition is filled in pharmaceutically acceptable capsules.

### Claim 51 (depends on 48)

The composition of claim 48, wherein said pharmaceutically acceptable capsule contains, as main polymer, gelatin, hydroxypropylcellulose or starch.

### Claim 52 (depends on 25)

The composition of claim 25, wherein the said dry powder composition is filled into a multidose dry powder inhaler device.
